Overview

A Study of NP-011 in Healthy Volunteers

Status:
Not yet recruiting

Trial end date:
2023-01-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1, randomised, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetic of NP-011 in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Nexel Co., Ltd.

Collaborator:

Novotech (Australia) Pty Limited